Recently, the Shanghai Municipal People's Government officially announced the winners of the Fifth Shanghai Intellectual Property Innovation Awards. Hua Medicine was honored with the Shanghai IPR Innovation Award (first prizes for patents) for its Chinese invention patent titled "Oral preparation of glucokinase activator and preparation method therefor". This recognition establishes the Company as a leading enterprise in intellectual property innovation within the biopharmaceutical industry.
Hua Medicine ("the Company", HKEX: 2552) announced that the Department of Health of the Hong Kong Special Administrative Region of China accepted a New Drug Application (NDA) for dorzagliatin, the world’s first glucokinase activator (GKA) approved for the treatment of Type 2 diabetes (T2D).
Hua Medicine (the “Company”, HKEx: 2552) announced the unaudited consolidated results of the Company and its subsidiaries for the six months ended June 30, 2025 (the “Reporting Period”), as well as the Company's business progress during the first half of the year and future outlook.
ir@huamedicine.com
No.275 Ai Di Sheng Road, Zhangjiang Hi-Tech Park, Pudong, Shanghai 201203
沪公网安备 31011502013809号 Privacy Statement Terms of Use
